NCT04725760 is a NA clinical trial of BrainPort Vision Pro in Blindness, sponsored by Wicab.

Who is sponsoring NCT04725760?

NCT04725760 is sponsored by Wicab.

What drugs are being tested in NCT04725760?

Interventions in NCT04725760: BrainPort Vision Pro.

Is NCT04725760 still recruiting?

NCT04725760 is currently status unknown. Last updated 10 November 2021.

Last reviewed 2021-11-10 · How we verify

NCT04725760

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population

Status unknown NA Last updated 10 November 2021

What this trial tests

NA trial testing BrainPort Vision Pro in Blindness in 125 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	Wicab
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	125
Start date	1 October 2020
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	7 locations across France

Drugs / interventions tested

BrainPort Vision Pro

Conditions studied

Blindness — all drugs for Blindness →

Sponsor

Wicab

Who can join

8 and older, any sex, with Blindness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the effectiveness and safety of the BrainPort® Vision Pro, an electronic oral assistive device, in the performance of daily tasks by French persons who have residual vision limited to light perception or less in both eyes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gene-agnostic approaches to treating inherited retinal degenerations.
Chew LA, Iannaccone A. · · 2023 · cited 14× · PMID 37123404 · DOI 10.3389/fcell.2023.1177838

Verify or expand the search:

Other recruiting trials for Blindness

Currently open trials in the same condition.

NCT06451172 — Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04725760 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wicab
Last refreshed: 10 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04725760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing